Barr (BRL) Shareholders Approval Proposed Acquisition of Teva (TEVA)
More News related to BRL
- Top 15 For 2008 (No. 14): M&A Wreckage
- Teva Completes Acquisition of Barr
- Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge
- U.S. Federal Trade Commission Clears Teva's Acquisition of Barr
- U.S. Federal Trade Commission Clears Teva's Acquisition of Barr
More News related to TEVA
- Teva to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
- Teva Announces Amir Elstein Joins Board of Directors
- Top 15 For 2008 (No. 14): M&A Wreckage
- XplosiveStocks.com: TEVA, ITRI, SBUX, DTV, GILD, BRCM Hot Stocks on the Move
- Teva Pharmaceutical (TEVA) volatility flat at 33
More News related to Mergers and Acquisitions
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Barr Pharmaceuticals, Inc. (NYSE: BRL) announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA).
"Today's vote demonstrated the overwhelming support of the transaction by the Barr shareholders," said Bruce L. Downey, Barr's Chairman and CEO. "We are pleased with the progress that we continue to make towards completion of the acquisition of Barr by Teva, and we and Teva continue to anticipate completing this transaction prior to the end of the year and combining our two strong organizations."
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients.[SM]
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00
-0.22Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
